IONS

IONS

USD

Ionis Pharmaceuticals Inc. Common Stock

$73.550-0.240 (-0.325%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$73.790

Hoch

$75.000

Tief

$72.360

Volumen

0.79M

Unternehmensfundamentaldaten

Marktkapitalisierung

11.9B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.47M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $23.95Aktuell $73.550Hoch $76.78

Ähnliche Nachrichten

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $110

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals with a Buy and raises the price target from $100 to $110.

Mehr anzeigen
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $110
Analyst Upgrades

Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $77

Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals with a Overweight and raises the price target from $70 to $77.

Mehr anzeigen
Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $77
Analyst Upgrades

TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $99

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals with a Buy and raises the price target from $59 to $99.

Mehr anzeigen
TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $99
Analyst Upgrades

Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $94

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals with a Overweight and raises the price target from $90 to $94.

Mehr anzeigen
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $94
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $100

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals with a Buy and raises the price target from $95 to $100.

Mehr anzeigen
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $100
Analyst Upgrades

Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $95

Barclays analyst Gena Wang maintains Ionis Pharmaceuticals with a Overweight and raises the price target from $80 to $95.

Analyst Upgrades

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $82

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals with a Outperform and raises the price target from $80 to $82.